RAPID BREATH DETECTION OF LUNG CANCER

肺癌的快速呼吸检测

• 批准号: 8497529
• 负责人: PAUL RHODES
• 金额: $ 97.14万
• 依托单位: ISENSE MEDICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-06-15 至 2014-06-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8497529
• 关键词: Adenocarcinoma Cell; Biological Assay; Breast; Breath Tests; Cancer Control; Cancer Detection; Cancer Patient; Cells; Clinic; Collection; Data Analyses; Detection; Development; Devices; Foundations; Gel; Generations; Lung; Malignant Neoplasms; Malignant neoplasm of lung; Medical; Metabolism; Modification; Monitor; Optics; Patients; Performance; Protocols documentation; Rest; Specificity; Staging; System; Technology; Testing; Treatment Efficacy; cancer diagnosis; cell type; chemotherapy; cost; next generation; sensor; tumor

The sensitivity of iSense Medical Corp (IMC) sensor system for the detection of a lung cancer signature from breath will be enhanced and demonstrated, a new breath collection device completed and a modification of the Cleveland Clinic Foundation (CCF) protocol for the ELDDA study of 8000 lung cancer patients and controls will be completed. The first generation of this non-invasive, inexpensice and rapid assay for the presence of lunf cancer has already been tested at CCF wwith specificity and selectivity of detection in the 80s. The next generation of this sensor array,comprising optical indicators embedded in a nanoporous sol-gel matrix is now>100x more sensitive to a range of lung cancer breath markers, enhancing sensitivty for a breast sensor technology already proven effective in lung cancer detection. The approved CCF protocol will be refined to assess the specific claim that following an indeterminate lung CT witht he IMC breath test reduces lung cancer diagnosis false positives over 200%. Further, as lung cancer breath signature arises from active tumor metabolism, the protocol will be adapted to test the hypothesis that the IMC breath rest represents a rapid and low-cost assessment for the efficacy of chemotherapy.

Isense Medical Corp（IMC）传感器系统对从呼吸中检测肺癌签名的敏感性将得到增强和证明，完成了新的呼吸收集装置，以及对8000个肺癌患者ELDDA研究的Cleveland Clinic Foundation（CCF）方案的修改，将完成。这种非侵入性，廉价和快速测定的LUNF癌症的第一代已经在80年代的CCF WWITH特异性和检测性的选择性上进行了测试。现在，该传感器阵列的下一代，包括嵌入在纳米孔溶胶胶体基质中的光学指标> 100倍，对一系列肺癌呼吸标记更敏感，从而增强了对已经在肺癌检测中有效的乳腺传感器技术的敏感性。批准的CCF方案将进行完善，以评估特定的主张，即在不确定的肺CT和IMC呼气测试后，肺癌诊断误差超过200％。此外，随着肺癌呼吸的签名是由主动肿瘤代谢引起的，该方案将适应以检验IMC呼吸休息的假设，即IMC呼吸休息代表了化学疗法疗效的快速和低成本评估。